Author

Mu Cheng

Observed names: Cheng, Mu, M.H. Cheng

Institution: Analysis Group (United States)

Observed institutions: The Alfred Hospital, Analysis Group (United States)

ORCID: 0000-0001-6831-0468

Observed ORCID: 0000-0001-6831-0468

OpenAlex ID: A5009702370

Comparative effectiveness of lenalidomide/dexamethasone-based triplet regimens for treatment of relapsed and/or refractory multiple myeloma in the United States: An analysis of real-world electronic health records data

2024 · Sikander Ailawadhi, Mu Cheng, et al. · Current Problems in Cancer · 4

Real-world perioperative treatment patterns and burden of recurrent disease in patients with high-risk endometrial cancer: a SEER-Medicare study

2024 · Vimalanand S. Prabhu, Kalé Kponee-Shovein, et al. · Journal of Medical Economics · 3

RANKL and OPG are expressed in malignant plasma cells of patients with multiple myeloma

2000 · H.G.F. Schneider, M.H. Cheng, et al. · Bone · 2

Health care costs among patients with relapsed/refractory multiple myeloma treated with ixazomib or daratumumab in combination with lenalidomide and dexamethasone in the United States

2024 · Sikander Ailawadhi, Mu Cheng, et al. · Journal of Managed Care & Specialty Pharmacy · 1

Correction: Clinical Burden of Recurrent Disease in High-Risk Endometrial Cancer

2025 · Kalé Kponee-Shovein, Vimalanand S. Prabhu, et al. · Oncology and Therapy

Clinical Burden of Recurrent Disease in High-Risk Endometrial Cancer

2025 · Kalé Kponee-Shovein, Vimalanand S. Prabhu, et al. · Oncology and Therapy

Works count: 8

Citation count: 10

H-index: 2

I10-index: